PURPOSE: To evaluate whether the addition of two biological markers ( @entity517 and @entity588 protein overexpression) improves the stratification of high-risk @entity1 with @entity1892 ( @entity1892 ). METHOD: Seven risk factors were identified at diagnosis, and a maximum of 7 points were assigned to each @entity1 . The @entity1 were classified according to four risk groups: low (0-1), low-intermediate (2-3), high-intermediate (4), and high (5-7). Only high-risk @entity1 with @entity1892 were included in this analysis. We retrospectively examined 20 cases from 2008 to 2013 at the Nanjing Drum Tower Hospital. RESULTS: The median expression of @entity517 protein was 60%, and 17 of 20 (65%) evaluable cases overexpressed @entity517 . The median expression of @entity588 protein was also 60%. Eighteen of 20 (90%) evaluable cases showed @entity588 overexpression. Additionally, 12 out of 20 cases (60%) demonstrated coexpression of @entity517 and @entity588 proteins. The percentages of overall survival and progression-free survival at the median follow-up time (36 months) were 33.3%  16.1% and 16.9%  13.5%, respectively. By comparison, nine, four, and 20 @entity1 were classified as high risk based on the International Prognostic Index (IPI), National @entity5 Network(NCCN)-IPI, and revised IPI criteria, respectively. According to the IPI and NCCN-IPI stratification, the risk groups demonstrated closely overlapping survival curves. In addition, four out of 20 cases were identified as low-intermediate risk according to the NCCN-IPI criteria. CONCLUSION: The addition of @entity517 and @entity588 protein expression to the IPI could identify a subset of @entity1892 @entity1 with high-risk clinicopathological characteristics and poor clinical outcome.

Combination of XXXX and @entity517 protein expression improves high-risk stratification in @entity1892 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity588 :: ('596', 'Gene') :: ['BCL-2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Comprehensive Cancer'] @entity517 :: ('4609', 'Gene') :: ['MYC'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'diffuse large B-cell lymphoma']
@entity588 :: (596,Gene) :: ['BCL-2']
